HomeCompareOTSKF vs ABBV

OTSKF vs ABBV: Dividend Comparison 2026

OTSKF yields 1.29% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $71.8K in total portfolio value
10 years
OTSKF
OTSKF
● Live price
1.29%
Share price
$70.34
Annual div
$0.91
5Y div CAGR
30.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$2,626.27
Full OTSKF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OTSKF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOTSKFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OTSKF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OTSKF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OTSKF
Annual income on $10K today (after 15% tax)
$109.97/yr
After 10yr DRIP, annual income (after tax)
$2,232.33/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $18,823.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OTSKF + ABBV for your $10,000?

OTSKF: 50%ABBV: 50%
100% ABBV50/50100% OTSKF
Portfolio after 10yr
$66.4K
Annual income
$13,699.01/yr
Blended yield
20.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OTSKF
No analyst data
Altman Z
5.2
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OTSKF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOTSKFABBV
Forward yield1.29%3.06%
Annual dividend / share$0.91$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR30.5%40.6%
Portfolio after 10y$30.5K$102.3K
Annual income after 10y$2,626.27$24,771.77
Total dividends collected$9.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OTSKF vs ABBV ($10,000, DRIP)

YearOTSKF PortfolioOTSKF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,869$168.83$11,550$430.00$681.00ABBV
2$11,853$223.80$13,472$627.96$1.6KABBV
3$12,981$297.68$15,906$926.08$2.9KABBV
4$14,287$397.59$19,071$1,382.55$4.8KABBV
5$15,821$533.70$23,302$2,095.81$7.5KABBV
6$17,649$720.80$29,150$3,237.93$11.5KABBV
7$19,865$980.70$37,536$5,121.41$17.7KABBV
8$22,602$1,346.27$50,079$8,338.38$27.5KABBV
9$26,052$1,868.16$69,753$14,065.80$43.7KABBV
10$30,502$2,626.27$102,337$24,771.77$71.8KABBV

OTSKF vs ABBV: Complete Analysis 2026

OTSKFStock

Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a conditioning beverage; EQUELLE and EQUELLE Gelée, which supports women's health and beauty; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; and OS-1, an oral rehydration solution. In addition, the company offers soft drinks, food products, and wines; clinical testing and medical equipment; cosmetics; warehousing and transport services; chemical products; travel agency services; analysis and measurement equipment; pharmaceutical intermediates; testing equipment, such as vehicle headlight testers; synthetic resin molded products; venture capital services; paper products; artificial turf; ceramic boards, ceramic board masterpiece arts, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; IT solution services; insecticides and toiletry products; and flaky titanate and special compounds. Further, it provides infusion and clinical nutrition products; Xenotransplantation products; hydrazine; plant-based food products, including cheese alternatives, dressings, and desserts; stable isotopes; software and services to enhance management of mental healthcare systems; products for urinary tract health; potassium titanate; bio-pesticides; functional and dietetic foods; spring and mineral water; industrial chemicals; polyolefin foams; anticancer drugs; and adhesive tapes. Additionally, the company operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.

Full OTSKF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OTSKF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OTSKF vs SCHDOTSKF vs JEPIOTSKF vs OOTSKF vs KOOTSKF vs MAINOTSKF vs JNJOTSKF vs MRKOTSKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.